Clinical Trial

Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled pilot study designed to evaluate the effect of an oral nutritional supplement containing Melissa officinalis formulated in phospholipids on mood and cortisol levels in healthy adults. Participants will be randomly assigned to receive either the active supplement or a placebo daily for 3 weeks. The primary outcome measures include changes in mood well-being, perceived stress, and salivary cortisol levels. The study aims to assess both efficacy and safety of the supplement in modulating stress response and emotional balance.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-17; most recent amendment 2025-11-23.
Trial Details
NCT Number NCT06942897
Lead Sponsor Azienda di Servizi alla Persona di Pavia
Conditions Stress, Mood Disorders, Emotional Well-being
Enrollment 40 participants
Start Date 2026-06-15
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-11-25